Compare SHG & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHG | DGX |
|---|---|---|
| Founded | 1982 | 1967 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9B | 23.1B |
| IPO Year | 2003 | 1996 |
| Metric | SHG | DGX |
|---|---|---|
| Price | $67.88 | $190.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $214.38 |
| AVG Volume (30 Days) | 205.6K | ★ 917.5K |
| Earning Date | 04-23-2026 | 04-21-2026 |
| Dividend Yield | ★ 2.12% | 1.82% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | N/A | ★ 2.24 |
| Revenue | N/A | ★ $11,035,000,000.00 |
| Revenue This Year | $5.16 | $7.53 |
| Revenue Next Year | $3.88 | $3.77 |
| P/E Ratio | ★ $9.79 | $85.70 |
| Revenue Growth | N/A | ★ 11.78 |
| 52 Week Low | $35.96 | $164.65 |
| 52 Week High | $73.40 | $213.50 |
| Indicator | SHG | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 56.83 | 42.76 |
| Support Level | $65.09 | $189.86 |
| Resistance Level | $69.85 | $193.04 |
| Average True Range (ATR) | 1.42 | 5.31 |
| MACD | -0.06 | -0.58 |
| Stochastic Oscillator | 62.61 | 15.88 |
Shinhan Financial Group Co Ltd is a Korean banking group. Along with its subsidiaries the company provides, comprehensive financial services which consist of commercial banking services, credit card services, securities services, insurance, credit services, and asset management services, including securities investment trust management, investment advisory, call transaction, domestic and foreign private equity fund business, and other services. The majority of the revenue is generated from its Banking business which includes retail, corporate, international, and other banking services the company offers.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.